secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptorum Group Ltd (APM)
CIK:        0001734005
Form:       8-K
Filed at:   2026-10-13T20:00:30+00:00
Accession:  0001213900-26-109016
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Niki BioSolutions names Thomas Freeburg CFO with $250K salary, 50,000 options at $8.83
--------------------------------------------------------------------------------

- Board appointed Thomas Freeburg, 59, as CFO on Oct 9, 2026; two-year term commencing Sept 1, 2026, reporting to CEO Ian Huen.
- Base salary $250,000, with $25,000 deferred until the company raises $3M cumulatively; rises to $275,000 at $5M raised; bonus up to 50% of salary.
- Receives 50,000 stock options at an $8.83 exercise price under the Niki BioSolutions 2026 Equity Incentive Plan; 20 days PTO and $150/month tech allowance.
- Qualifying termination severance: lump sum of remaining base salary through end of Initial Term or six months, whichever is greater, plus COBRA and full unvested equity acceleration.
- Freeburg was CFO/Secretary/Treasurer of Interpace Biosciences (IDXG) from Feb 2021 to Mar 2023, with earlier SEC reporting roles at Tapestry (TPR) and Scholastic (SCHL).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/0001213900-26-109016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/ea0308307-8k_niki.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-109016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer